Ispire Technology Earnings Call Signals Cost-Driven Reset

Ispire Technology, Inc. ((ISPR)) has held its Q2 earnings call. Read on for the main highlights of the call.

Ispire Technology’s latest earnings call painted a picture of a business at a strategic turning point. Executives stressed better collections, leaner operations and progress in new technologies, even as revenue and gross profit were cut roughly in half and cash flow turned negative, leaving investors weighing long‑term promise against near‑term strain.

Accounts Receivable and Collections Improvement

Ispire reported a sharp cleanup in its balance sheet, with net accounts receivable falling to $37.9 million from $47.0 million and days sales outstanding improving by eight days. Cash collected versus revenue for calendar 2025 surged to 116% from 67%, signaling that the company is getting paid faster and tightening credit to customers.

Operating Expense Reductions

Management underscored aggressive cost discipline, cutting operating expenses to $10.3 million from $15.1 million, a drop of nearly 32%. The leaner structure is central to the turnaround narrative, as the company looks to support future growth without returning to prior spending levels.

Lower Net Loss

Despite steep revenue pressure, Ispire narrowed its net loss to $6.6 million from $8.0 million in the prior-year quarter. Over the six months ended December 31, 2025, net loss improved by $3.7 million year over year, suggesting that cost measures are starting to offset the weaker top line.

Minimal Operating Cash Burn in H2 2025

From April through year-end 2025, operating cash burn was limited to just $1.0 million, reflecting tighter working capital and expense control. This low burn rate offers some comfort to investors concerned about liquidity while the revenue base is being reshaped.

Strategic Pivot to Higher-Quality Nicotine Customers

The company continued its pivot away from lower-value cannabis and slower-paying customers toward higher-quality nicotine clients. This shift has hurt short-term sales but materially improved receivables and collection metrics, aligning the business with customers seen as more sustainable and profitable.

Progress on iQTEC Age-Gating Technology

Ispire’s iQTEC age-gating platform advanced its regulatory and commercial footprint, including a component application submitted in May 2024 and growing industry interest. A development agreement with Charlie’s aims to start shipping 2–3 million chips per month within two to three months, with ambitions to ramp to 10 million devices monthly over time.

Regulatory Engagement and Risk

Management highlighted deeper engagement with regulators, including an invitation to a U.S. roundtable for small manufacturers, positioning iQTEC within policy discussions. Still, executives cautioned that commercialization timing hinges on regulatory outcomes, keeping revenue contributions uncertain in the near term.

Gmesh Technology and Malaysian Capacity Expansion

The company’s Gmesh superconductive-glass hardware is drawing commercial interest, and manufacturing is being scaled to match. A Malaysian facility expansion from six production lines toward 80 lines is underway, intended to support future volume as the strategic mix shifts toward higher-value hardware.

Improved Investing and Financing Cash Trends

Capital deployment was notably restrained, with net cash used in investing activities at $0.9 million versus $1.1 million a year earlier. Financing cash outflows were also modest at $0.7 million, suggesting that the company is preserving financial flexibility while it restructures operations.

Sharp Revenue Decline

The most visible cost of Ispire’s pivot came on the top line, as revenue plunged to $20.3 million from $41.8 million, a drop of more than 51%. Management linked the decline to exiting lower-value and cannabis-focused accounts, indicating intentional pruning rather than pure demand erosion.

Gross Profit and Margin Compression

Gross profit fell to $3.5 million from $7.7 million, roughly a 55% decrease, and gross margin slipped to 17.1% from 18.5%. The margin pressure was tied primarily to product mix, with fewer higher-margin products sold during the quarter as the customer portfolio shifted.

Decline in Cash Balance

Cash on hand declined to $17.6 million from $24.4 million at June 30, 2025, underscoring tighter liquidity. While management pointed to improving cash discipline, the smaller cushion heightens the importance of stabilizing cash flow in coming quarters.

Operating Cash Flow Turned Negative

For the six months to December 31, 2025, net cash used in operating activities totaled $5.2 million, compared with $0.4 million of cash provided a year earlier. This deterioration reflects the revenue drop and timing effects, even as second-half burn moderated sharply.

Revenue Timing and Regulatory Dependency

Executives tempered expectations for immediate volume from age-gating, saying current-quarter uplift is unlikely. Broader commercialization depends on regulatory approvals and successful launches with partners, creating timing and execution risk around when iQTEC meaningfully adds to revenue.

Illicit Market and Chinese Supply Headwinds

The U.S. nicotine market remains dominated by illicit products, which management estimated at more than 90% of volume, pressuring compliant players. At the same time, changes in Chinese export incentives have driven shipment spikes and pricing pressure, adding volatility to an already challenging environment.

Mandate Uncertainty and Potential Funding Needs

Although global interest in age-gating is rising, no jurisdiction has fully mandated such technology, and many discussions remain confidential. Management acknowledged that the iQTEC joint venture may require additional capital to scale worldwide, implying possible financing or dilution down the road.

Guidance and Forward-Looking Outlook

Looking ahead, management guided to continued top-line growth, steadier cash flow and further bottom-line improvement in fiscal 2026, expecting recent operational trends to persist. The company is banking on its Malaysian expansion and iQTEC rollout, with initial chip volumes targeted at a few million units per month and longer-term ambitions of scaling to tens of millions of devices.

Ispire’s earnings call delivered a cautiously optimistic message: near-term numbers are weak, but operations and strategy are improving. For investors, the story now hinges on whether regulatory tailwinds, capacity expansion and higher-quality customers can translate into sustainable growth before cash constraints start to bite.